Reduction of platinum(IV) prodrug model complex trans-[PtCl2(CN)4]2− by a peptide containing cysteine and methionine groups: HPLC and MS studies

Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs

“…However, experimental data suggest that the reduction of Pt(IV) prodrugs by glutathione leads to a cisplatin–glutathione adduct, which is not as toxic as free cisplatin to the cancer cell [ 20 ]. As far as the external medium is concerned, there are reducing species that might activate the prodrug before it reaches the cell, e.g., the thiol groups present in cysteine, thioglycolic acid and methionine [ 21 ]. The external activation might occur through an outer-sphere electron transfer mechanism, in which a six-coordinated Pt(III) intermediate is formed by the addition of a single electron before the prodrug reaches the cell [ 22 ].…”

Advances in technical strategies for monitoring the reduction of platinum(iv) complexes

“…4B). 68,69 The identification of reduction products, including the Pt(II) counterparts and the released axial ligands, can be achieved by comparing their respective retention times.…”

Pt(iv) complex selectively oxidizes alpha-synuclein methionine as disclosed by NMR

“…Pt(IV) complexes, the next generation of platinum drugs, have been developed to address the issues of classical Pt(II) drugs including the onset of severe side effects, intrinsic resistance and general toxicity. [23][24][25][26][27][28] Pt(IV) complexes are thought to be activated by intracellular sulfur-containing small molecules, ascorbic acid (VC), and cysteine-containing proteins, 24,[29][30][31][32] while methionine and cysteine, [33][34][35] dGMP, 36 serum albumin, 37 and flavoproteins 38 have been reported to reduce platinum(IV) complexes. Recent studies have showed that some platinum(IV) complexes are resistant to glutathione (GSH) but are rapidly reduced in cancer cells or cell lysates, and high molecular weight species (MW > 3000 Dalton) were therefore proposed for activating Pt(IV).…”